Ultragenyx has recently published its 2022 ESG Report, highlighting its commitment to corporate responsibility within the biopharmaceutical industry. This comprehensive report delves into Ultragenyx’s dedication to innovation, patient support, community impact, environmental sustainability, and robust governance. Focused on rare and ultrarare diseases, Ultragenyx has made significant strides, such as advancing multiple gene therapies, expanding clinical trials globally, and delivering treatments to over 3,200 patients.
The company also actively participates in initiatives supporting education, public health, and local communities, exemplified by substantial charitable donations and grants. Environmental responsibility is paramount, with a notable emphasis on renewable energy adoption and waste reduction. Additionally, Ultragenyx maintains strong corporate governance, prioritizing data protection and security. These achievements have garnered Ultragenyx multiple awards. For further details, you can explore the full report on Ultragenyx’s corporate responsibility efforts here.